{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:26:02Z","timestamp":1787135162446,"version":"build-2736575974"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Repeated administration of mRNA vaccines against SARS-CoV-2 has been associated with qualitative changes in antibody responses, including the emergence of non-inflammatory IgG4 subclasses and changes in Fc glycosylation. While neutralizing antibody titers remain key correlates of protection, potential functional implications of these structural antibody features warrant further investigation across age groups and multiple mRNA vaccine boosters. We characterized spike-specific IgG responses\u2014including subclasses and Fc glycosylation patterns\u2014using a liquid chromatography\u2014mass spectrometry-based approach across six mRNA vaccine doses in a Swedish healthcare worker cohort (n\u2009=\u2009104) and across three mRNA doses in a Singaporean pediatric cohort (n\u2009=\u200918). Repeated mRNA vaccination induced an IgG4 class switch which was sustained across at least six doses. This response associated with an increased risk of breakthrough infection (HR = 1.83,\u00a0p\u2009=\u20090.028) in infection-na\u00efve individuals (n\u2009=\u200941) lacking mucosal IgA responses that would potentially confound the interpretation of systemic IgG4\u2011related infection outcomes. Moreover, the IgG4 class switch was preceded with high early IgG1 Fc fucosylation signatures. Notably, these IgG structural changes were observed primarily in individuals who were na\u00efve to SARS-CoV-2 at the time of first vaccination. Similar IgG structural features were observed across three mRNA doses in the small infection-naive pediatric cohort. Our results illustrate an IgG4-dominated immunological signature in both adults and children and highlight that immune priming by prior infection may shape subsequent mRNA vaccine-induced antibody responses. While these findings do not call into question the efficacy or safety of the widely adapted mRNA vaccine platform, they may have implications that merit further investigation.<\/jats:p>","DOI":"10.1038\/s41598-026-64190-8","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:24:51Z","timestamp":1786519491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8089-4352","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Pongr\u00e1cz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Marking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Bladh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherina","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Berkell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Havervall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Greilert-Norin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Gijze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wasynczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Falck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Th\u00e5lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"64190_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201. https:\/\/doi.org\/10.1056\/NEJMoa2101544 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"64190_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson, M. G. et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N. Engl. J. Med. 385, 1355\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2110362 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMoa2107659 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475\u2013484. https:\/\/doi.org\/10.1038\/s41577-021-00578-z (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"64190_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch, D. H. Covid-19 vaccines - immunity, variants, boosters. N. Engl. J. Med. 387, 1011\u20131020. https:\/\/doi.org\/10.1056\/NEJMra2206573 (2022).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41590-023-01544-8","volume":"24","author":"F Nimmerjahn","year":"2023","unstructured":"Nimmerjahn, F., Vidarsson, G. & Cragg, M. S. Effect of posttranslational modifications and subclass on IgG activity: From immunity to immunotherapy. Nat. Immunol. 24, 1244\u20131255. https:\/\/doi.org\/10.1038\/s41590-023-01544-8 (2023).","journal-title":"Nat. Immunol."},{"key":"64190_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","volume":"23","author":"T Rispens","year":"2023","unstructured":"Rispens, T. & Huijbers, M. G. The unique properties of IgG4 and its roles in health and disease. Nat. Rev. Immunol. 23, 763\u2013778. https:\/\/doi.org\/10.1038\/s41577-023-00871-z (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"64190_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8378","author":"MD Larsen","year":"2021","unstructured":"Larsen, M. D. et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science https:\/\/doi.org\/10.1126\/science.abc8378 (2021).","journal-title":"Science"},{"key":"64190_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10719-022-10044-0","volume":"39","author":"T Pongracz","year":"2022","unstructured":"Pongracz, T., Vidarsson, G. & Wuhrer, M. Antibody glycosylation in COVID-19. Glycoconj. J. 39, 335\u2013344. https:\/\/doi.org\/10.1007\/s10719-022-10044-0 (2022).","journal-title":"Glycoconj. J."},{"key":"64190_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.it.2024.06.003","volume":"45","author":"A Izadi","year":"2024","unstructured":"Izadi, A. & Nordenfelt, P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 45, 609\u2013624. https:\/\/doi.org\/10.1016\/j.it.2024.06.003 (2024).","journal-title":"Trends Immunol."},{"key":"64190_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106317","volume":"89","author":"AM Marchese","year":"2024","unstructured":"Marchese, A. M. et al. Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines. J. Infect. 89, 106317. https:\/\/doi.org\/10.1016\/j.jinf.2024.106317 (2024).","journal-title":"J. Infect."},{"key":"64190_CR15","doi-asserted-by":"publisher","first-page":"eade2798","DOI":"10.1126\/sciimmunol.ade2798","volume":"8","author":"P Irrgang","year":"2023","unstructured":"Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8, eade2798. https:\/\/doi.org\/10.1126\/sciimmunol.ade2798 (2023).","journal-title":"Sci. Immunol."},{"key":"64190_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40103-x","volume":"13","author":"P Kiszel","year":"2023","unstructured":"Kiszel, P. et al. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Sci. Rep. 13, 13166. https:\/\/doi.org\/10.1038\/s41598-023-40103-x (2023).","journal-title":"Sci. Rep."},{"key":"64190_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/all.16241","author":"JS Buhre","year":"2024","unstructured":"Buhre, J. S. et al. Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination. Allergy https:\/\/doi.org\/10.1111\/all.16241 (2024).","journal-title":"Allergy"},{"key":"64190_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106119","volume":"88","author":"R Kalkeri","year":"2024","unstructured":"Kalkeri, R. et al. Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines. J. Infect. 88, 106119. https:\/\/doi.org\/10.1016\/j.jinf.2024.106119 (2024).","journal-title":"J. Infect."},{"key":"64190_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29793","volume":"96","author":"S Reinig","year":"2024","unstructured":"Reinig, S. et al. Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines. J. Med. Virol. 96, e29793. https:\/\/doi.org\/10.1002\/jmv.29793 (2024).","journal-title":"J. Med. Virol."},{"key":"64190_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1020844","volume":"13","author":"JS Buhre","year":"2022","unstructured":"Buhre, J. S. et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front. Immunol. 13, 1020844. https:\/\/doi.org\/10.3389\/fimmu.2022.1020844 (2022).","journal-title":"Front. Immunol."},{"key":"64190_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-024-00466-9","volume":"21","author":"AT Gelderloos","year":"2024","unstructured":"Gelderloos, A. T. et al. Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults. Immun. Ageing 21, 63. https:\/\/doi.org\/10.1186\/s12979-024-00466-9 (2024).","journal-title":"Immun. Ageing"},{"key":"64190_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13090944","author":"L Yao","year":"2025","unstructured":"Yao, L. et al. SARS-CoV-2 infection or COVID-19 mRNA vaccination elicits partially different spike-reactive memory B cell responses in na\u00efve individuals. Vaccines https:\/\/doi.org\/10.3390\/vaccines13090944 (2025).","journal-title":"Vaccines"},{"key":"64190_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172470","author":"KJ Selva","year":"2023","unstructured":"Selva, K. J. et al. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.172470 (2023).","journal-title":"JCI Insight"},{"key":"64190_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2023.11.028","volume":"139","author":"M Yoshimura","year":"2024","unstructured":"Yoshimura, M. et al. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines. Int. J. Infect. Dis. 139, 1\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.028 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"64190_CR25","doi-asserted-by":"publisher","first-page":"1309997","DOI":"10.3389\/fimmu.2023.1309997","volume":"14","author":"M Akhtar","year":"2023","unstructured":"Akhtar, M. et al. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Front. Immunol. 14, 1309997. https:\/\/doi.org\/10.3389\/fimmu.2023.1309997 (2023).","journal-title":"Front. Immunol."},{"key":"64190_CR26","doi-asserted-by":"publisher","first-page":"2547517","DOI":"10.1080\/21645515.2025.2547517","volume":"21","author":"E Berber","year":"2025","unstructured":"Berber, E., Jarrett, E. E., Hanley, H. B., Uno, N. & Ross, T. M. Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections. Hum. Vaccin. Immunother. 21, 2547517. https:\/\/doi.org\/10.1080\/21645515.2025.2547517 (2025).","journal-title":"Hum. Vaccin. Immunother."},{"key":"64190_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107990","volume":"159","author":"AS Siebner","year":"2025","unstructured":"Siebner, A. S. et al. Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees. Int. J. Infect. Dis. 159, 107990. https:\/\/doi.org\/10.1016\/j.ijid.2025.107990 (2025).","journal-title":"Int. J. Infect. Dis."},{"key":"64190_CR28","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1038\/s41598-024-71047-5","volume":"14","author":"AI Portilho","year":"2024","unstructured":"Portilho, A. I. et al. An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Sci. Rep. 14, 20003. https:\/\/doi.org\/10.1038\/s41598-024-71047-5 (2024).","journal-title":"Sci. Rep."},{"key":"64190_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106473","volume":"90","author":"C Martin Perez","year":"2025","unstructured":"Martin Perez, C. et al. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections. J. Infect. 90, 106473. https:\/\/doi.org\/10.1016\/j.jinf.2025.106473 (2025).","journal-title":"J. Infect."},{"key":"64190_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1043049","volume":"13","author":"YS Goh","year":"2022","unstructured":"Goh, Y. S. et al. Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections. Front. Microbiol. 13, 1043049. https:\/\/doi.org\/10.3389\/fmicb.2022.1043049 (2022).","journal-title":"Front. Microbiol."},{"key":"64190_CR31","doi-asserted-by":"publisher","first-page":"eadg7327","DOI":"10.1126\/sciimmunol.adg7327","volume":"8","author":"S Pillai","year":"2023","unstructured":"Pillai, S. Is it bad, is it good, or is IgG4 just misunderstood?. Sci Immunol 8, eadg7327. https:\/\/doi.org\/10.1126\/sciimmunol.adg7327 (2023).","journal-title":"Sci Immunol"},{"key":"64190_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front. Immunol. 8, 877. https:\/\/doi.org\/10.3389\/fimmu.2017.00877 (2017).","journal-title":"Front. Immunol."},{"key":"64190_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107619","author":"J Van Coillie","year":"2023","unstructured":"Van Coillie, J. et al. Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines. iScience https:\/\/doi.org\/10.1016\/j.isci.2023.107619 (2023).","journal-title":"iScience"},{"key":"64190_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104408","author":"J Van Coillie","year":"2023","unstructured":"Van Coillie, J. et al. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees. EBioMedicine https:\/\/doi.org\/10.1016\/j.ebiom.2022.104408 (2023).","journal-title":"EBioMedicine"},{"key":"64190_CR35","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1021\/acs.jproteome.4c00538","volume":"23","author":"S Gijze","year":"2024","unstructured":"Gijze, S. et al. Simultaneous protein quantitation and glycosylation profiling of antigen-specific immunoglobulin G1 in large clinical studies. J. Proteome Res. 23, 5600\u20135605. https:\/\/doi.org\/10.1021\/acs.jproteome.4c00538 (2024).","journal-title":"J. Proteome Res."},{"key":"64190_CR36","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S1473-3099(23)00421-8","volume":"23","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. Mucosal IgA protects against BQ.1 and BQ.1.1 infection. Lancet Infect. Dis. 23, e272\u2013e273. https:\/\/doi.org\/10.1016\/S1473-3099(23)00421-8 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"64190_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMc2209651","volume":"387","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N. Engl. J. Med. 387, 1333\u20131336. https:\/\/doi.org\/10.1056\/NEJMc2209651 (2022).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41467-023-36984-1","volume":"14","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nat. Commun. 14, 1577. https:\/\/doi.org\/10.1038\/s41467-023-36984-1 (2023).","journal-title":"Nat. Commun."},{"key":"64190_CR39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213153","author":"F Zuo","year":"2022","unstructured":"Zuo, F., Marcotte, H., Hammarstrom, L. & Pan-Hammarstrom, Q. Mucosal IgA against SARS-CoV-2 Omicron infection. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2213153 (2022).","journal-title":"N. Engl. J. Med."},{"key":"64190_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00900","volume":"8","author":"VMW Gould","year":"2017","unstructured":"Gould, V. M. W. et al. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front. Microbiol. 8, 900. https:\/\/doi.org\/10.3389\/fmicb.2017.00900 (2017).","journal-title":"Front. Microbiol."},{"key":"64190_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02372-23","volume":"15","author":"R Bean","year":"2024","unstructured":"Bean, R. et al. Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers. MBio 15, e02372-02323. https:\/\/doi.org\/10.1128\/mbio.02372-23 (2024).","journal-title":"MBio"},{"key":"64190_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113. https:\/\/doi.org\/10.1038\/s41586-021-03738-2 (2021).","journal-title":"Nature"},{"key":"64190_CR43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K Roltgen","year":"2022","unstructured":"Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025-1040 e1014. https:\/\/doi.org\/10.1016\/j.cell.2022.01.018 (2022).","journal-title":"Cell"},{"key":"64190_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1128\/cdli.9.3.693-697.2002","volume":"9","author":"MB Isa","year":"2002","unstructured":"Isa, M. B. et al. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin. Diagn. Lab. Immunol. 9, 693\u2013697. https:\/\/doi.org\/10.1128\/cdli.9.3.693-697.2002 (2002).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"64190_CR45","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","volume":"177","author":"CW Davis","year":"2019","unstructured":"Davis, C. W. et al. Longitudinal analysis of the human B Cell response to Ebola virus infection. Cell 177, 1566\u20131582. https:\/\/doi.org\/10.1016\/j.cell.2019.04.036 (2019).","journal-title":"Cell"},{"key":"64190_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08526-5","volume":"7","author":"S Chaudhury","year":"2017","unstructured":"Chaudhury, S. et al. Delayed fractional dose regimen of the RTS,S\/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis. Sci. Rep. 7, 7998. https:\/\/doi.org\/10.1038\/s41598-017-08526-5 (2017).","journal-title":"Sci. Rep."},{"key":"64190_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106543","volume":"91","author":"R Kalkeri","year":"2025","unstructured":"Kalkeri, R. et al. Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprinting. J. Infect. 91, 106543. https:\/\/doi.org\/10.1016\/j.jinf.2025.106543 (2025).","journal-title":"J. Infect."},{"key":"64190_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116000","volume":"44","author":"JCH Tam","year":"2025","unstructured":"Tam, J. C. H. et al. Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses. Cell Rep. 44, 116000. https:\/\/doi.org\/10.1016\/j.celrep.2025.116000 (2025).","journal-title":"Cell Rep."},{"key":"64190_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/imm.13531","volume":"167","author":"W Chen","year":"2022","unstructured":"Chen, W. et al. The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine. Immunology 167, 221\u2013232. https:\/\/doi.org\/10.1111\/imm.13531 (2022).","journal-title":"Immunology"},{"key":"64190_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00919-8","volume":"9","author":"GE Hartley","year":"2024","unstructured":"Hartley, G. E. et al. Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding. NPJ Vaccines 9, 129. https:\/\/doi.org\/10.1038\/s41541-024-00919-8 (2024).","journal-title":"NPJ Vaccines"},{"key":"64190_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1727049","volume":"16","author":"J Meyer","year":"2025","unstructured":"Meyer, J. et al. Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations. Front. Immunol. 16, 1727049. https:\/\/doi.org\/10.3389\/fimmu.2025.1727049 (2025).","journal-title":"Front. Immunol."},{"key":"64190_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105912","volume":"120","author":"U Marking","year":"2025","unstructured":"Marking, U. et al. Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection. EBioMedicine 120, 105912. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105912 (2025).","journal-title":"EBioMedicine"},{"key":"64190_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106087","volume":"123","author":"KJ Selva","year":"2026","unstructured":"Selva, K. J. et al. Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses. EBioMedicine 123, 106087. https:\/\/doi.org\/10.1016\/j.ebiom.2025.106087 (2026).","journal-title":"EBioMedicine"},{"key":"64190_CR54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029553","author":"DA Diavatopoulos","year":"2017","unstructured":"Diavatopoulos, D. A. & Edwards, K. M. What is wrong with pertussis vaccine immunity? Why immunological memory to pertussis is failing. Cold Spring. Harb. Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a029553 (2017).","journal-title":"Cold Spring. Harb. Perspect Biol."},{"key":"64190_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.it.2022.08.001","volume":"43","author":"JJ Oosterhoff","year":"2022","unstructured":"Oosterhoff, J. J., Larsen, M. D., van der Schoot, C. E. & Vidarsson, G. Afucosylated IgG responses in humans\u2014Structural clues to the regulation of humoral immunity. Trends Immunol. 43, 800\u2013814. https:\/\/doi.org\/10.1016\/j.it.2022.08.001 (2022).","journal-title":"Trends Immunol."},{"key":"64190_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8654","author":"W Hoepel","year":"2021","unstructured":"Hoepel, W. et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf8654 (2021).","journal-title":"Sci. Transl. Med."},{"key":"64190_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm7853","volume":"14","author":"S Chakraborty","year":"2022","unstructured":"Chakraborty, S. et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci. Transl. Med. 14, eabm7853. https:\/\/doi.org\/10.1126\/scitranslmed.abm7853 (2022).","journal-title":"Sci. Transl. Med."},{"key":"64190_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41590-020-00828-7","volume":"22","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S. et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat. Immunol. 22, 67\u201373. https:\/\/doi.org\/10.1038\/s41590-020-00828-7 (2021).","journal-title":"Nat. Immunol."},{"key":"64190_CR59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","volume":"606","author":"E Sefik","year":"2022","unstructured":"Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585\u2013593. https:\/\/doi.org\/10.1038\/s41586-022-04802-1 (2022).","journal-title":"Nature"},{"key":"64190_CR60","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","volume":"606","author":"C Junqueira","year":"2022","unstructured":"Junqueira, C. et al. FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 606, 576\u2013584. https:\/\/doi.org\/10.1038\/s41586-022-04702-4 (2022).","journal-title":"Nature"},{"key":"64190_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx7231","volume":"17","author":"U Ashraf","year":"2025","unstructured":"Ashraf, U. et al. Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination. Sci. Transl. Med. 17, eadx7231. https:\/\/doi.org\/10.1126\/scitranslmed.adx7231 (2025).","journal-title":"Sci. Transl. Med."},{"key":"64190_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100818","author":"P Bharadwaj","year":"2022","unstructured":"Bharadwaj, P. et al. Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation. Cell Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100818 (2022).","journal-title":"Cell Rep. Med."},{"key":"64190_CR63","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.4049\/jimmunol.2100399","volume":"207","author":"TLJ van Osch","year":"2021","unstructured":"van Osch, T. L. J. et al. Fc galactosylation promotes hexamerization of human IgG1, leading to enhanced classical complement activation. J. Immunol. 207, 1545\u20131554. https:\/\/doi.org\/10.4049\/jimmunol.2100399 (2021).","journal-title":"J. Immunol."},{"key":"64190_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/glycob\/cwaa018","volume":"30","author":"EB Irvine","year":"2020","unstructured":"Irvine, E. B. & Alter, G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology 30, 241\u2013253. https:\/\/doi.org\/10.1093\/glycob\/cwaa018 (2020).","journal-title":"Glycobiology"},{"key":"64190_CR65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/glycob\/cwz065","volume":"30","author":"BA Cobb","year":"2020","unstructured":"Cobb, B. A. The history of IgG glycosylation and where we are now. Glycobiology 30, 202\u2013213. https:\/\/doi.org\/10.1093\/glycob\/cwz065 (2020).","journal-title":"Glycobiology"},{"key":"64190_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103957","author":"T Pongracz","year":"2022","unstructured":"Pongracz, T. et al. Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19. EBioMedicine https:\/\/doi.org\/10.1016\/j.ebiom.2022.103957 (2022).","journal-title":"EBioMedicine"},{"key":"64190_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abh2259","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abh2259 (2021).","journal-title":"Sci. Immunol."},{"key":"64190_CR68","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M111.014563","volume":"11","author":"MH Selman","year":"2012","unstructured":"Selman, M. H. et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol. Cell. Proteomics 11, M111.014563. https:\/\/doi.org\/10.1074\/mcp.M111.014563 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"64190_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087532","volume":"14","author":"N Oskam","year":"2023","unstructured":"Oskam, N. et al. Factors affecting IgG4-mediated complement activation. Front. Immunol. 14, 1087532. https:\/\/doi.org\/10.3389\/fimmu.2023.1087532 (2023).","journal-title":"Front. Immunol."},{"key":"64190_CR70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527. https:\/\/doi.org\/10.1038\/s41586-020-2798-3 (2020).","journal-title":"Nature"},{"key":"64190_CR71","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.chom.2021.06.016","volume":"29","author":"K Subbarao","year":"2021","unstructured":"Subbarao, K. The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host Microbe 29, 1111\u20131123. https:\/\/doi.org\/10.1016\/j.chom.2021.06.016 (2021).","journal-title":"Cell Host Microbe"},{"key":"64190_CR72","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1097\/INF.0000000000004557","volume":"44","author":"T Ohnishi","year":"2025","unstructured":"Ohnishi, T., Erdem, G., Kuno, T. & Yasuhara, J. mRNA vaccines: Future perspectives for children. Pediatr. Infect. Dis. J. 44, e49\u2013e52. https:\/\/doi.org\/10.1097\/INF.0000000000004557 (2025).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"64190_CR73","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960. https:\/\/doi.org\/10.1038\/s41586-024-07539-1 (2024).","journal-title":"Nature"},{"key":"64190_CR74","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156. https:\/\/doi.org\/10.1038\/s41586-023-06753-7 (2024).","journal-title":"Nature"},{"key":"64190_CR75","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/INF.0000000000004488","volume":"43","author":"R Kobbe","year":"2024","unstructured":"Kobbe, R. et al. Delayed induction of noninflammatory SARS-CoV-2 spike-specific IgG4 antibodies detected 1 year after BNT162b2 vaccination in children. Pediatr. Infect. Dis. J. 43, 1200\u20131203. https:\/\/doi.org\/10.1097\/INF.0000000000004488 (2024).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"64190_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00512-X","author":"AK Blakney","year":"2026","unstructured":"Blakney, A. K. et al. Safety and efficacy of mRNA vaccines: A mechanistic and public health perspective. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(26)00512-X (2026).","journal-title":"Lancet"},{"key":"64190_CR77","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1016\/S2666-5247(23)00102-7","volume":"4","author":"O Bladh","year":"2023","unstructured":"Bladh, O. et al. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe 4, e488. https:\/\/doi.org\/10.1016\/S2666-5247(23)00102-7 (2023).","journal-title":"Lancet Microbe"},{"key":"64190_CR78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/joim.13387","volume":"291","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J. Intern. Med. 291, 72\u201380. https:\/\/doi.org\/10.1111\/joim.13387 (2022).","journal-title":"J. Intern. Med."},{"key":"64190_CR79","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1473-3099(22)00834-9","volume":"23","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect. Dis. 23, 150\u2013152. https:\/\/doi.org\/10.1016\/S1473-3099(22)00834-9 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"64190_CR80","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41591-024-02962-3","volume":"30","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y. et al. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children. Nat. Med. 30, 1373\u20131383. https:\/\/doi.org\/10.1038\/s41591-024-02962-3 (2024).","journal-title":"Nat. Med."},{"key":"64190_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-00963-7","author":"D Falck","year":"2024","unstructured":"Falck, D. & Wuhrer, M. Glycolisa: Antigen-specific and subclass-specific IgG Fc glycosylation analysis based on an immunosorbent assay with an LC-MS readout. Nat. Protoc. https:\/\/doi.org\/10.1038\/s41596-024-00963-7 (2024).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64190-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64190-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64190-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:44:37Z","timestamp":1787132677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64190-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64190"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64190-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the work has been construed in the absence of competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26038"}}